Internal Medicine, Hematology & Oncology · Reno, NV
NPI
1740712108
Since 2017
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5423 Reno Corporate Dr
Reno, NV, 89511
Phone (775) 329-0222
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
78,012 services
Medicare patients, 2024
273
Average age 75
Drug cost, 2024
$2.9M
1,011 prescriptions
Company payments, 2025
$3,657
From 34 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Colt Williams was code J1100 (injection, dexamethasone sodium phosphate, 1 mg), 1,520 times for 31 patients. In total Colt Williams billed 78,012 services in 102 codes, and Medicare paid $1.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-08-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,520 | 31 | $0.09 | $136 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,070 | 29 | $0.70 | $753 |
| 99215 Office E&M - Established | Office | 424 | 115 | $147.44 | $63K |
| 96375 Injection Administration | Office | 390 | 40 | $12.71 | $4,957 |
| 99214 Office E&M - Established | Office | 255 | 130 | $102.58 | $26K |
| J9045 Injection, carboplatin, 50 mg | Office | 243 | 12 | $2.88 | $701 |
| 36415 Venipuncture Blood Collection | Office | 242 | 114 | $8.61 | $2,085 |
| 96413 Chemotherapy Administration | Office | 233 | 49 | $107.03 | $25K |
| 96417 Chemotherapy Administration | Office | 93 | 24 | $52.79 | $4,910 |
| 96415 Chemotherapy Administration | Office | 92 | 18 | $22.93 | $2,110 |
| 99205 Office E&M - New | Office | 86 | 86 | $176.12 | $15K |
| J7030 Infusion, normal saline solution , 1000 cc | Office | 82 | 11 | $2.07 | $170 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 68 | 21 | $0.64 | $43.66 |
| 99233 Hospital E&M - Subsequent | Facility | 61 | 22 | $96.25 | $5,871 |
| 99204 Office E&M - New | Office | 57 | 57 | $127.42 | $7,263 |
By year: 2022 $27K for 198 services; 2023 $230K for 12,322 services; 2024 $1.8M for 78,012 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 242 | 114 | $8.61 | $2,085 |
Medicare prescription drug claims, 2024
In 2024, the drug Colt Williams prescribed most often to Medicare patients was Olanzapine, with 69 prescriptions and refills. In total Colt Williams wrote 1,011 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Olanzapine Generic | 69 | 85 | 26 | $1,128 |
| Ondansetron Hcl Generic | 47 | 47 | 31 | $646 |
| Dexamethasone Generic | 45 | 47 | 18 | $701 |
| Prochlorperazine Maleate Generic | 38 | 38 | 28 | $419 |
| Keytruda Pembrolizumab | 34 | 34 | Under 11 | $381K |
| Potassium Chloride Generic | 29 | 31 | 13 | $252 |
| Hydroxyurea Generic | 29 | 57 | Under 11 | $426 |
| Prednisone Generic | 28 | 30 | 13 | $186 |
| Gabapentin Generic | 24 | 24 | Under 11 | $195 |
| Levofloxacin Generic | 22 | 24 | 12 | $385 |
| Revlimid Lenalidomide | 21 | 21 | Under 11 | $258K |
| Acyclovir Generic | 21 | 29 | Under 11 | $240 |
| Venclexta Venetoclax | 20 | 20 | Under 11 | $215K |
| Levothyroxine Sodium Generic | 20 | 32 | Under 11 | $133 |
| Imfinzi Durvalumab | 19 | 19 | Under 11 | $245K |
Brand drugs: 295 claims; generic drugs: 716 claims; opioid claims: 32.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Colt Williams $3,657 ($3,657 in general payments such as food, travel and fees) from 34 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,149.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 15 | $1,149 |
| Daiichi Sankyo Inc. 4568.T | 15 | $914 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $219 |
| Astellas Pharma US Inc 4503.T | 5 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 7 | $141 |
| Genzyme Corporation SNY | 4 | $119 |
| Abbvie Inc. ABBV | 4 | $83.98 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $72.09 |
| PharmaEssentia USA Corporation 6446.TW | 2 | $55.21 |
| Genentech USA, Inc. ROG.SW | 2 | $52.24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.